Things aren’t always as they seem. Take pancreatic cancer, for example. In up to one in 10 cases, researchers have documented a peculiar characteristic.
Tomivosertib hydrochloride by EFFECTOR Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes
October 27, 2023